Skip to content
value.today
Endra Life Sciences Inc. logo

Endra Life Sciences Inc.

NDRA
$7 Mmarket cap on Oct 30, 2026-38.3% since Jan 2024
Compare
World rank
#26,385
Revenue
—
For year ending December-2025
Net income
$-7 M
SEC filing
Employees
11
As of December 31, 2025
SEC filing

Endra Life Sciences Inc. in brief

Endra Life Sciences Inc. is a listed company in the Diagnostics and Research industry, based in Ann Arbor, Michigan, USA. Its market value was $7 M on 30 October 2026, which makes it the 26,385th largest listed company in the world and the 4,347th largest in the USA on this site. It employs about 11 people and Alexander Y. Tokman is its chief executive. Its shares trade under the symbol NDRA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Endra Life Sciences Inc.

We were incorporated as a Delaware corporation in 2007. We are developing a next-generation enhanced ultrasound technology platform—Thermo- Acoustic Enhanced Ultrasound, or TAEUS®.

We have periodically evaluated and refined our vision, purpose, and go-to-market strategy with respect to TAEUS in response to evolving market conditions and development priorities.

We plan to offer a multi-year, subscription-based business model with recurring revenue, while continuing to support traditional capital equipment sales with associated service and upgrade offerings.

From the company's annual report filed with the US SEC: read the report

Endra Life Sciences Inc. timeline

3 events, 2016–2017
  1. 2016
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed ENDRA Life Sciences Inc.
    Formerly Endra Inc..
  4. 2017
  5. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 10 May 2017; shares registered for exchange trading on 4 May 2017.

Events of Endra Life Sciences Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$8 M$16 M$24 M$32 M2020202120222023202420252026

World rank over time

▼ down 1,039 places since 2020
2020-01-01: #25352#25,35220202021-01-01: #22716#22,71620212022-01-07: #28701#28,70120222022-12-25: #29876#29,87620222023-07-30: #31732#31,73220232024-01-05: #30558#30,55820242026-03-08: #13255#13,25520262026-08-01: #23448#23,44820262026-10-30: #26391#26,3912026

Rank in USA: #4,519 (Jan 2020) · #4,335 (Jan 2021) · #5,180 (Jan 2022) · #5,354 (Dec 2022) · #5,458 (Jul 2023) · #4,478 (Jan 2024) · #2,455 (Mar 2026) · #4,099 (Aug 2026) · #4,350 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.3×
Free cash flow yield
-70.2%
Net margin
—
Operating margin
—
Return on equity
-311.1%
Liabilities / assets
41.3%
Net debt
$-3M
Revenue growth
-97.1%
R&D / revenue
47200.0%
Profit per employee
$-639 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-10M$0MFY18Fiscal year ending Dec 2019: revenue —, net income $-13M—FY19Fiscal year ending Dec 2020: revenue —, net income $-12M—FY20Fiscal year ending Dec 2021: revenue —, net income $-11M—FY21Fiscal year ending Dec 2022: revenue —, net income $-13M—FY22Fiscal year ending Dec 2023: revenue —, net income $-10M—FY23Fiscal year ending Dec 2024: revenue —, net income $-12M—FY24Fiscal year ending Dec 2025: revenue —, net income $-7M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-6M$-7M—
Dec 2024——$-11M$-12M—
Dec 2023——$-11M$-10M—
Dec 2022——$-13M$-13M—
Dec 2021——$-12M$-11M—
Dec 2020——$-12M$-12M—
Dec 2019——$-11M$-13M—
Dec 2018$0M—$-9M$-10M-98000.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-5M$0M$-5M$-8.93—
Dec 2024$-7M$0M$-7M$-56.94—
Dec 2023$-10M$0M$-10M$-2766.85—
Dec 2022$-13M$0M$-13M——
Dec 2021$-11M$0M$-11M——
Dec 2020$-11M$0M$-11M$-0.63—
Dec 2019$-9M$0M$-9M$-2.34—
Dec 2018$-8M$0M$-8M$-2.17—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-2M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-1M—Mar ’25Three months to Jun 2025: revenue —, net income $-1M—Jun ’25Three months to Sep 2025: revenue —, net income $-2M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-3M—Dec ’25Three months to Mar 2026: revenue —, net income $-1M—Mar ’26Three months to Jun 2026: revenue —, net income $0M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Endra Life Sciences Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-6 M
Net income
$-7 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$4 M
Total liabilities
$2 M
Total equity
$2 M

As of December-2025

Top 12 institutional investors in Endra Life Sciences Inc.#

As of Sep 30, 2026
12 institutions held 166,275 shares (about 11.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 11.0%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 12 largest institutional investors in Endra Life Sciences Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Altium Capital Management LLC54,528-4,744 (-8.00%)3.64%$0 MNov 4, 2026
2Citizens Financial Group Inc/ri28,4000 (0.00%)1.89%$0 MOct 23, 2026
3Citadel Advisors LLC20,745-9,179 (-30.67%)1.38%$0 MNov 16, 2026
4Renaissance Technologies LLC18,764New1.25%$0 MNov 12, 2026
5Geode Capital Management, LLC14,9100 (0.00%)0.99%$0 MNov 6, 2026
6Vanguard Fiduciary Trust Co10,1210 (0.00%)0.67%$0 MNov 13, 2026
7Vanguard Capital Management LLC7,3390 (0.00%)0.49%$0 MNov 13, 2026
8UBS Group AG5,942+5,874 (+8638.24%)0.40%$0 MNov 10, 2026
9Morgan Stanley3,5460 (0.00%)0.24%$0 MNov 13, 2026
10Citigroup Inc1,078New0.07%$0 MNov 4, 2026
11Tower Research Capital LLC (TRC)883+825 (+1422.41%)0.06%$0 MNov 16, 2026
12Northwestern Mutual Wealth Management Co190 (0.00%)0.00%$0 MNov 13, 2026

Mutual funds holding Endra Life Sciences Inc.#

3 funds hold shares worth $0 M (about 1.6% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding Endra Life Sciences Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC14,580$0 M0.97%<0.01%+138%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.7,339$0 M0.49%<0.01%+161%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,597$0 M0.11%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Endra Life Sciences Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
12
since
Endra Life Sciences Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Alexander Y. TokmanChief Executive Officer, DirectorGrant or award+26,921——101,926Form 4
filed Richard JacrouxChief Financial OfficerGrant or award+13,461——33,461Form 4
filed Michael HarshDirectorGrant or award+60,324——65,710Form 4
filed Anthony DigiandomenicoDirectorGrant or award+60,324——136,589Form 4
filed Lou BaseneseDirectorGrant or award+60,324——65,709Form 4
filed Alexander Y. TokmanChief Executive Officer, DirectorGrant or award+75,000——75,005Form 4
filed Richard JacrouxChief Financial OfficerGrant or award+20,000——20,000Form 4
filed Anthony DigiandomenicoDirectorGrant or award+70,822$7.060$500 K76,265Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Endra Life Sciences Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
23,275
2.0% of shares · 1.97 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-11-17 17:21 UTC, code LUDP, resumed 17:26 UTC
  • 2026-06-25 13:57 UTC, code LUDP, resumed 14:02 UTC
  • 2026-06-25 13:47 UTC, code LUDP, resumed 13:52 UTC
  • 2026-06-25 13:36 UTC, code LUDP, resumed 13:46 UTC
  • 2026-06-25 13:30 UTC, code LUDP, resumed 13:35 UTC

Fails to deliver

  • : 2 shares at $4.94
  • : 1,941 shares at $6.46
  • : 2,173 shares at $5.61
  • : 2,761 shares at $5.54
  • : 2,780 shares at $5.49

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Endra Life Sciences Inc. scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median3.3×Price to book 3.3× against Diagnostics and Research's median of 3.7×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-70.2%Free cash flow is -70.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-8.93 vs -56.94Diluted EPS -8.93 in fiscal 2025 against -56.94 the year before (report's currency).
    • ✓Net income higher than five years earlier-$7 M-$7 M in fiscal 2025 against -$12 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-291.7%-291.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities1.3×Current ratio 1.29 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year289.6%Diluted shares up 289.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Endra Life Sciences Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Endra Life Sciences Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue—————000.00.40.5
Cost of revenue—————0000.2—
Gross profit—————000.00.20.3
Research and development1.83.25.06.65.55.96.64.71.90.5
Selling and marketing0.20.60.81.41.10.60.40.30.10.0
General and administrative3.77.14.75.24.95.03.93.82.81.5
Operating expenses5.81111131112119.04.82.1
Operating income−5.8−11−11−13−11−12−11−9.0−4.6−1.8
Interest expense and finance costs———————00.00.1
Other non-operating income (expense)−1.3−0.70.5−0.00.3−0.2−2.5−0.8−0.8—
Income before tax−7.0−12−10−13−11−12−13−9.8−5.4−2.8
Income tax—000000000
Net income including minority interests—−12−10131112r−13−9.8−5.4−2.8
Net income attributable to shareholders−7.0−12−10−13−11−12−13−9.8−5.4−2.8
Earnings per share, basic-8.93-56.94—-4.56-5.55r-0.63-2.34-2.17-1.95-3.84
Earnings per share, diluted-8.93-56.94-2,766.85——-0.63-2.34-2.17-1.95-3.84
Shares, weighted average (basic)0.80.2————————
Shares, weighted average (diluted)0.80.20.0——197.54.52.80.7
Balance sheet
Cash and cash equivalents0.83.22.84.99.57.26.26.55.60.1
Receivables———————00.00
Inventory002.62.61.30.60.10.10.20.0
Other current assets—————0.00.10.30.00.0
Current assets1.03.43.05.4r128.2r6.56.95.9r0.2r
Property, plant and equipment0.00.10.10.20.10.20.20.30.20.3
Right-of-use (leased) assets0.50.60.40.50.60.30.40——
Total assets3.94.56.89.3138.87.27.26.1r0.5
Accounts payable0.40.30.40.60.80.41.30.60.8r0.2
Current liabilities0.80.60.91.71.51.02.11.00.8r1.4
Lease liabilities (non-current)0.40.50.20.40.50.30.30——
Non-current liabilities0.81.30.20.4—0.60.30——
Total liabilities1.61.91.12.12.11.62.41.00.8r1.4
Retained earnings−110−103−92−82−69−57−45−28−18−13
Shareholders' equity2.32.65.77.2117.2r4.86.25.3−0.9
Total liabilities and equity3.94.56.89.3138.87.27.26.1r0.5
Shares outstanding1.20.50.0r3.22.1r348.47.43.90.7
Cash-flow statement
Depreciation and amortization0.00.00.10.10.10.10.10.10.10.1
Share-based compensation0.30.61.01.21.42.1————
Cash from operating activities−5.2−7.4−9.5−13−11−11−8.6−7.7−3.3r−1.3
Capital expenditure−0.0−0.0−0.0−0.2−0.0−0.1−0.0−0.1−0.0—
Intangible assets bought−3.0—————————
Cash from investing activities−3.0−0.0−0.0−0.2−0.0−0.1−0.0−0.1−0.00
Debt repaid—−0.0————————
Shares issued1.25.4r6.58.4116.80.17.78.60.0
Cash from financing activities5.77.87.58.413128.38.78.81.4
Report10-K10-K10-K/A10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Endra Life Sciences Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2024
$215 K
Alexander Tokman
Other top executives, average
$148 K
the CEO earned 1.5× this
$100 invested is now
$30
Endra Life Sciences Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2024Alexander Tokman$215 K$195 K$148 K$30

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2024

Events at Endra Life Sciences Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Restructuring 1 · Change in control 1 · Directors and officers 2 · Material agreement 5 · Agreement ended 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 1 · Results announced 6

Endra Life Sciences Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreement8-K
Results announced8-K
Change in controlMaterial agreement8-K
Material agreementUnregistered share sale8-K
Delisting notice8-K
Results announced8-K
Restructuring8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Material agreement8-K
Material agreementAgreement endedUnregistered share sale8-K/A
Results announced8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 1, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Endra Life Sciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$14 MPrivate placement after listing$10 to $50 million6equitySEC
Dec 2019$9 MPrivate placement after listing$2 to $10 million151equity, debtSEC
Jul 2019$3 MPrivate placement after listing$2 to $10 million86debt, optionsSEC
Jun 2018$1 MPrivate placement after listingUnder $2 million18equity, debtSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Endra Life Sciences Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
0
2026–2026
Latest
—
2026-03-19
Endra Life Sciences Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
Endra Life Sciences Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Endra Life Sciences Inc. compares in Diagnostics and Research

  • Market cap$7 M · higher than 10% of 110
  • Revenue growth-97.1% · higher than 0% of 89
  • Price / book3.3× · lower than 45% of 84
  • FCF yield-70.2% · higher than 8% of 66

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
Endra Life Sciences Inc.🇺🇸$7 M——-97.1%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 18, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Endra Life Sciences Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Endra Life Sciences Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Endra Life Sciences Inc.? Suggest a correction